A compact, to the point edition was just emailed to subscribers and archived. Subscribe to NFTRH Premium for an in-depth weekly market report, interim updates and NFTRH+ chart and trade…
Just a quick note that the pre-Christmas push has got me behind the 8 ball and this week's abbreviated NFTRH report will be delivered tomorrow, Sunday, as usual.
I don't how many subscribers I've either lost or never had the pleasure of serving over the years because of my conservative nature and need not to do as those…
Each week these reports help me find the right balance between the obviously bullish trends going on out there and the risks inherent. This report is no different, and also…
Though I am loath to talk too much about stocks and stock trading, I get it. I get that some people want a practical way to see what my transactions…
Just doing the work as the 3 Amigos ride on... Subscribe to NFTRH Premium for an in-depth weekly market report, interim updates and NFTRH+ chart and trade ideas; or the…
Back on November 21 I noted that MarketWatch was playing the usual mainstream media role of bringing people to the party way too late and indeed, endangering them. They put…
We compact #476 all the way down to 58 pages! Don't laugh, for me lately that's an achievement. I am trying to pull in some of the far ranging explorations…
A big thank you to all of the NFTRH subscribers who took the time to take me up on a request for feedback. With yesterday's 75 page report and the…
Good report, on top of the market's trends and going with them; but not afraid to look ahead either. Subscribe to NFTRH Premium for an in-depth weekly market report, interim…
Out yesterday, actually. Just able to get to the promo now. #474 does all the usual updating of US and global markets, along with a focus on Medical Device industry…
Do yourself and me a favor. If you're going to view this as a stock pick service or evaluate performance within the span of a couple or few weeks don't…
In NFTRH 472 we noted sentiment and indicator risks to this über büllish market. On Wednesday morning in a pre-market update we noted the extreme overbought condition after Dow and…
The near-term 'yields rising' play is still alive and while it is testing my patience, still the favored scenario. But I am well aware that the anti-yield Biotech sector for…